Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial

Published:2016-01 Issue:1 Volume:6 Page:e378-e378
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Raje N,Vadhan-Raj S,Willenbacher W,Terpos E,Hungria V,Spencer A,Alexeeva Y,Facon T,Stewart A K,Feng A,Braun A,Balakumaran A,Roodman G D

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/bcj201596.pdf

Reference20 articles.

1. Coleman RE . Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243s–6249s.

2. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813–822.

3. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132–5139.

4. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125–1132.

5. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; 48: 3082–3092.

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathophysiology and therapeutic advances in myeloma bone disease;Chronic Diseases and Translational Medicine;2022-07-04

2. The Osteoclast Traces the Route to Bone Tumors and Metastases;Frontiers in Cell and Developmental Biology;2022-05-13

3. The Roadmap of RANKL/RANK Pathway in Cancer;Cells;2021-08-04

4. Individualized Bone‐Protective Management in Long‐Term Cancer Survivors With Bone Metastases;Journal of Bone and Mineral Research;2021-06-24

5. Impact of MGUS and myeloma on skeletal health;Marcus and Feldman's Osteoporosis;2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3